Preliminary data on the relationship between nortriptyline plasma level and response in depressed children

Area of Science:

• Child and Adolescent Psychiatry
• Pharmacology
• Clinical Psychology

Background:

• Major Depressive Disorder (MDD) is a significant mental health concern in children.
• Nortriptyline is a tricyclic antidepressant used in pediatric depression treatment.
• Determining optimal dosing for pediatric patients remains a challenge.

Purpose of the Study:

• To investigate the relationship between nortriptyline plasma levels and treatment response in children with MDD.
• To establish a therapeutic plasma concentration range for nortriptyline in pediatric patients.
• To compare the efficacy of a fixed milligram-per-kilogram dose versus a pharmacokinetic approach.

Main Methods:

• Twenty-two children aged 6-12 diagnosed with MDD received a fixed daily dose of nortriptyline for 8 weeks.
• Weekly plasma nortriptyline levels were monitored.
• Behavioral assessments were conducted by blinded raters unaware of plasma levels.

Main Results:

• A significant difference was observed in mean steady-state plasma levels between responders and nonresponders.
• The data suggest a lower limit for the therapeutic range of nortriptyline in children is over 60 ng/ml.
• This range is comparable to that established for adult patients.

Conclusions:

• Nortriptyline plasma levels are a critical determinant of treatment efficacy in pediatric depression.
• A therapeutic window of over 60 ng/ml for nortriptyline in children is suggested.
• Pharmacokinetic monitoring is advantageous over simple milligram-per-kilogram dosing for optimizing nortriptyline treatment in children.